
Performance · Recovery · Longevity
Catalogue
Browse “Muscle/Performamnce, Recovery/Tissue, Weight Loss/Metabolic and Research Peptides“ and advanced wellness compounds. Prices are shown in South African Rand (ZAR).
Select a product to view available quantities, specifications and regulatory status. Quantities, documentation and pricing are confirmed before dispatch.
Tirzepatide 30mg (Peptide Aesthetix UPZEP)
|
Category: |
Weight Loss / Metabolic / Longevity |
|
Price: |
R 1800.00 |
|
{{variant.name}}:
|
{{opt.name}}
{{opt.name}}
|
TEST RUN WELLNESS UPZEP 30 | Tirzepatide 30mg Self-Mix Vial
UPZEP 30 (Tirzepatide 30mg) – High-purity dual-agonist peptide for effective glucose management and fat loss. Self-mix vial. Advanced weight management.
Product Overview
UPZEP 30 is a Tirzepatide 30mg self-mix vial. Tirzepatide is a first-in-class dual agonist that selectively binds to and activates both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors.
It is a 39-amino-acid modified peptide with a C20 fatty diacid moiety that enables albumin binding and prolongs its half-life, allowing for once-weekly dosing.
How Tirzepatide Works: Dual GIP/GLP-1 Pathway Agonist
Tirzepatide enhances first- and second-phase insulin secretion and reduces glucagon levels, both in a glucose-dependent manner. The GIP component plays a role in nutrient and energy metabolism, while the GLP-1 component delays gastric emptying, suppresses appetite, and improves satiety.
Research has shown that downstream interaction between GLP-1 and GIP agonism is required for synergistic effects on body weight, with the dorsal vagal complex playing a key role in mediating these actions.
Tirzepatide's biased binding mode, with C-terminal mutations weakening GLP-1R affinity and N-terminal mutations enhancing GIPR affinity, contributes to its unique pharmacological profile.
Body Recomposition Benefits
Clinical evidence demonstrates that tirzepatide induces favourable body composition changes, characterised by predominant fat loss and relative preservation of lean mass.
In a real-world study, approximately 78% of total weight loss was attributable to fat mass reduction, with the relative proportion of lean mass increasing by 3.00 percentage points despite a modest decrease in absolute soft lean mass. In the SURMOUNT-1 trial, approximately 75% of body weight lost was fat mass.
Combining tirzepatide with resistance exercise, adequate protein intake, and structured lifestyle modification has been associated with increased skeletal muscle mass and grip strength despite a net decrease in lean body mass.
These findings support tirzepatide as a metabolically favourable agent for body recomposition when paired with supportive lifestyle strategies.
Titration Protocol
Tirzepatide should be initiated at 2.5 mg injected subcutaneously once weekly for 4 weeks. The dose may then be increased in 2.5 mg increments after at least 4 weeks on the current dose, up to a maximum of 15 mg weekly. A standard escalation schedule is as follows:
· Week 1–4: 2.5 mg once weekly
· Week 5–8: 5 mg once weekly
· Week 9–12: 7.5 mg once weekly
· Week 13–16: 10 mg once weekly
· Week 17–20: 12.5 mg once weekly
· Week 21+: 15 mg once weekly (maximum maintenance dose)
Dose escalation should only proceed if the current dose is well tolerated. Maintenance doses for weight reduction are typically 5 mg, 10 mg, or 15 mg weekly.
Combination Therapy
Combination therapies represent a promising strategy to enhance the efficacy and tolerability of incretin-based treatments. Dual agonists such as tirzepatide have demonstrated superior weight loss and glycaemic control compared to GLP-1 receptor agonists alone, likely due to complementary mechanisms involving both incretin pathways.
Triple agonists targeting GLP-1, GIP, and glucagon receptors (such as retatrutide) are in development and have shown even greater weight loss effects in early-phase trials. Other potential combinations include GLP-1 receptor agonists with SGLT-2 inhibitors, amylin analogues, or central nervous system appetite modulators.
Preclinical research has also explored tirzepatide combined with leptin, demonstrating synergistic effects on weight loss and metabolic homeostasis in diet-induced obesity models. All combination approaches should be pursued under professional medical supervision.
Technical Specifications
Product Name: UPZEP 30
Peptide: Tirzepatide
Concentration: 30mg per vial
Form: Self-mix vial
Supplier: Test Run Wellness (Wellness.testrun)
⚕️ Important Medical Notice
Please consult your medical practitioner regarding your body requirements, as the dosing information provided contains guideline dosages. UPZEP 30 is intended for use under professional medical supervision.
Regulatory notice. Test Run Wellness is an independent supplier and is not the manufacturer of the products referenced. No product should be used without appropriate regulatory authorisation and professional medical oversight.